Cantor Fitzgerald sets USD 120 target for Vaxcyte stock

Published on 10/20/2026 at 18:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vaxcyte lost USD 284.30 million in the second quarter. Vaxcyte stock costs EUR 58.75 on October 20, 2026 at 6:17 p.m. CEST.

Analyst target and cash position

Cantor Fitzgerald set a USD 120.00 target and kept an Overweight rating on October 19, 2026.
Vaxcyte posted a USD 284.30 million net loss in the second quarter of 2026.
Vaxcyte stock costs EUR 58.75 at Lang & Schwarz on October 20, 2026 at 6:17 p.m. CEST.
Cash, cash equivalents and investments totaled USD 2.51 billion at June 30, 2026.

PCVX, US92243G1085, Illustration mit AI erstellt.

Cantor Fitzgerald reiterated its Overweight rating on Vaxcyte and set a USD 120.00 price target on October 19, 2026, according to Investing.com. Cantor lifted its estimated adult probability of success to 90 percent from 75 percent after OPUS-1 data. Vaxcyte stock was trading at EUR 58.75 at Lang & Schwarz on October 20, 2026 at 6:17 p.m. CEST.

Target rests on VAX-31 progress

The analyst action keeps attention on VAX-31, Vaxcyte's 31-valent pneumococcal conjugate vaccine. The OPUS-1 adult Phase 3 trial met all prespecified primary endpoints on October 5, 2026, including 20 of 20 shared-serotype comparisons against Prevnar 20, according to Alliance Equity Research. The result supports the development case, but the report also noted that manufacturing consistency and regulatory review remain part of the path to a filing.

Losses rise with clinical spending

Vaxcyte reported a USD 284.30 million net loss in the second quarter of 2026, while research and development expense reached USD 267.85 million. Operating cash use was USD 232.47 million in the quarter, based on the period figures. The latest quarter therefore combined a larger development budget with continued cash consumption.

Cash supports the next stages

Cash, cash equivalents and investments totaled USD 2.51 billion at June 30, 2026, according to Alliance Equity Research. MarketBeat reported that nine analysts covered Vaxcyte on October 18, 2026, with seven Buy ratings, one Hold and one Sell, and an average 12-month target of USD 110.50.MarketBeat

What comes next for Vaxcyte?

Vaxcyte expects OPUS-2 and OPUS-3 results in the first half of 2027. The company also plans a biologics license application for VAX-31 in the first half of 2028, according to Alliance Equity Research. For investors, the key balance is the USD 120.00 target against a clinical-stage business that still reported no revenue in the second quarter and continues to fund costly trials.

Nasdaq-listed biotech with a broad pipeline

Vaxcyte is listed on Nasdaq under PCVX and develops protein-based vaccines for bacterial diseases. Its lead programs include VAX-31 and VAX-24, while the early-stage pipeline includes candidates targeting Group A Strep and Shigella. The company ended June 2026 with USD 2.51 billion in cash, giving its clinical programs financial runway while development spending remains elevated. The stock's primary-market quote was USD 66.49 on Nasdaq on October 20, 2026 at 12:30 p.m. ET.

Vaxcyte was trading at EUR 58.75 at Lang & Schwarz on October 20, 2026 at 6:17 p.m. CEST. The current analyst range places the next valuation debate around clinical execution, cash use and the timing of VAX-31 evidence. The further course of trading is shown by the continuously updated real-time quote of Vaxcyte stock.